Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis?
Is Negativity of Autoantibodies a Marker of Severity in Auto-immune Hepatitis
Centre Hospitalier Universitaire de la Guadeloupe
100 participants
Jul 1, 2022
OBSERVATIONAL
Conditions
Summary
Evaluate the proportion of seronegative auto-immune hepatitis and a possible relationship with the severity of the disease. Criteria of severity will be defined by corticodependance, corticoresistance and a severe form of the disease at diagnosis (cirrhosis or fulminant hepatitis). In case of predominant seronegative forms, other auto-antibodies related to this auto-immue hepatitis will be searched.
Eligibility
Inclusion Criteria4
- \- Any patient over 18 years old
- Patient followed at Hôpital Saint-Antoine or treated for HAI or in Guadeloupe within the framework of the CCRD Filfoie for an acute or chronic AIH under immunosuppressive treatment
- Patient affiliate or beneficiary of a social security scheme
- Free, informed and written consent signed by the patient and the investigator
Exclusion Criteria10
- Patient not able to give his/her consent
- Viral hepatitis: viruses A to E, Epstein-Barr virus, cytomegalovirus and herpes simplex virus
- Isolated primary biliary cholangitis
- Isolated primary sclerosing cholangitis
- Drug-induced liver injury
- Wilson disease
- Alcoholic hepatitis
- Hemochromatosis
- Sickle cell disease and heart liver
- Non-alcoholic steato-hepatitis
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
For the study, a blood sample will be collected from the patient in order to do build up a serological library which will allow the search for rare autoAb whose interest has been demonstrated as prognostic factors of the disease.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06761209